Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer

被引：11

作者：

Igawa, Satoshi ^{[1
]}

Ryuge, Shinichiro ^{[1
]}

Fukui, Tomoya ^{[1
]}

Otani, Sakiko ^{[1
]}

Kimura, Yuka ^{[1
]}

Katono, Ken ^{[1
]}

Takakura, Akira ^{[1
]}

Kubota, Masaru ^{[1
]}

Mitsufuji, Hisashi ^{[1
]}

Katagiri, Masato ^{[2
]}

Yanase, Nobuo ^{[3
]}

Masuda, Noriyuki ^{[1
]}

机构：

[1] Kitasato Univ, Sch Med, Dept Resp Med, Kanagawa 2280022, Japan

[2] Kitasato Univ, Dept Clin Physiol, Sch Allied Hlth Sci, Kanagawa 2280022, Japan

[3] Kitasato Univ, Dept Nursing, Kanagawa 2280022, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 15卷 / 05期

关键词：

Amrubicin; First line; SCLC; Elderly; Poor risk; ONCOLOGY-GROUP WJTOG; PHASE-II; ORAL ETOPOSIDE; CARBOPLATIN; TRIAL; JAPAN; 9-AMINOANTHRACYCLINE; CHEMOTHERAPY; SM-5887;

D O I：

10.1007/s10147-010-0085-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study was conducted to evaluate the efficacy of amrubicin as first-line chemotherapy for elderly and poor-risk patients with extensive-disease small-cell lung cancer (ED-SCLC). Untreated SCLC patients who were > 75 years of age or had a performance status of 2 or more were eligible. Amrubicin (35 or 40 mg/m(2) on days 1-3 every 3 weeks) was administered. Between January 2003 and May 2009, 27 patients were evaluated. The median number of treatment cycles was 4 (1-6). Grade 3 or 4 hematologic toxicities comprised neutropenia (63%), leukopenia (56%), thrombocytopenia (15%), and anemia (19%). Febrile neutropenia was observed in four (15%) patients. No treatment-related deaths occurred. The nonhematologic toxicities were mild. The overall response rate was 70%. Progression-free survival, median survival time, and the 1-year survival rate were 6.6 months, 9.3 months, and 30%, respectively. The 40 mg/m(2) dose was feasible and had a tendency to be more effective than the 35 mg/m(2) dose. Amrubicin exhibits activity and acceptable toxicities for elderly and poor-risk patients with ED-SCLC in the first-line treatment setting.

引用

页码：447 / 452

页数：6

共 18 条

[1] ORAL ETOPOSIDE AND CARBOPLATIN - EFFECTIVE THERAPY FOR ELDERLY PATIENTS WITH SMALL-CELL LUNG-CANCER [J].